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Abstract
Context: 17α-Hydroxylase/17,20-lyase deficiency (17OHD) caused by mutations in the CYP17A1 gene is a rare form of 
congenital adrenal hyperplasia typically characterised by cortisol deficiency, mineralocorticoid excess and sex  
steroid deficiency.
Objective: To examine the phenotypic spectrum of 17OHD by clinical and biochemical assessment and corresponding 
in silico and in vitro functional analysis.
Design: Case series.
Patients and results: We assessed eight patients with 17OHD, including four with extreme 17OHD phenotypes: two 
siblings presented with failure to thrive in early infancy and two with isolated sex steroid deficiency and normal 
cortisol reserve. Diagnosis was established by mass spectrometry-based urinary steroid profiling and confirmed by 
genetic CYP17A1 analysis, revealing homozygous and compound heterozygous sequence variants. We found novel 
(p.Gly111Val, p.Ala398Glu, p.Ile371Thr) and previously described sequence variants (p.Pro409Leu, p.Arg347His, 
p.Gly436Arg, p.Phe53/54del, p.Tyr60IlefsLys88X). In vitro functional studies employing an overexpression system in 
HEK293 cells showed that 17,20-lyase activity was invariably decreased while mutant 17α-hydroxylase activity retained 
up to 14% of WT activity in the two patients with intact cortisol reserve. A ratio of urinary corticosterone over cortisol 
metabolites reflective of 17α-hydroxylase activity correlated well with clinical phenotype severity.
Conclusion: Our findings illustrate the broad phenotypic spectrum of 17OHD. Isolated sex steroid deficiency with 
normal stimulated cortisol has not been reported before. Attenuation of 17α-hydroxylase activity is readily detected by 
urinary steroid profiling and predicts phenotype severity.
Significance statement
Here we report, supported by careful phenotyping, genotyping and functional analysis, a prismatic case series of 
patients with congenital adrenal hyperplasia due to 17α-hydroxylase (CYP17A1) deficiency (17OHD). These range 
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in severity from the abolition of function, presenting in early infancy, and unusually mild with isolated sex steroid 
deficiency but normal ACTH-stimulated cortisol in adult patients. These findings will guide improved diagnostic 
detection of CYP17A1 deficiency.
Introduction
The classic phenotypic presentation of 17α-hydroxylase 
deficiency (17OHD) comprises cortisol and sex steroid 
deficiency combined with mineralocorticoid excess (1). 
Affected genetic males (46,XY) commonly present with 
female external genitalia at birth, are usually raised as girls 
and are often not diagnosed until they reach adolescent age 
when they present with pubertal delay and hypertension, 
similar to 46,XX females. Patients typically escape the 
adrenal crisis, despite being profoundly cortisol deficient, 
due to the affinity of accumulating corticosterone for the 
glucocorticoid receptor (1, 2).
The molecular bases of 17OHD are inactivating 
mutations in the CYP17A1 gene, coding for an enzyme that 
is located at a major branch point in human steroidogenesis. 
CYP17A1 (also P450c17) exhibits two distinct catalytic 
activities. CYP17A1 17α-hydroxylase activity is crucial 
for cortisol biosynthesis in the adrenal by converting 
progesterone and pregnenolone to 17-hydroxyprogesterone 
(17OHP) and 17-hydroxypregnenolone (17Preg), 
respectively, the 21-carbon precursors of cortisol. CYP17A1 
17,20-lyase activity generates sex steroids in adrenal and 
gonads by converting 17OHP to androstenedione and, 
with about 50-fold higher efficiency (3), 17Preg to DHEA, 
the principal androgen precursor in humans. CYP17A1 
requires electron transfer from NAD phosphate (NADPH). 
For sufficient reaction efficiency, the flavoprotein P450 
oxidoreductase (POR) is crucial for both catalytic steps (4, 
5) and the small haemoprotein cytochrome b5 (CYB5A) for 
efficient 17,20-lyase activity (6).
To date, more than 100 mutations in the CYP17A1 
gene have been described (www.hgmd.cf.ac.uk), and 
the majority are associated with a classic phenotype of 
combined 17α-hydroxylase/17,20-lyase deficiency. A 
smaller number of CYP17A1 missense variants are reported 
to exhibit partial impairment of 17α-hydroxylase/17,20-
lyase activity, where hypertension is mild or absent and 
external genitalia appear ambiguous in 46,XY individuals 
(7, 8, 9, 10, 11). A small number of individuals affected 
by 17OHD present with apparently isolated 17,20-lyase 
deficiency, with abolished or severely reduced 17,20-
lyase activity but only mild to moderate impairment 
of 17α-hydroxylase activity (12, 13, 14). These patients 
had normal blood pressure and random cortisol levels 
but reduced sex steroid production. This suggests that 
variations in CYP17A1 17α-hydroxylase activity determine 
the width of the phenotypic spectrum of 17OHD.
We have analysed a series of eight patients with 17OHD 
including four patients with novel phenotypes at opposite 
ends of the phenotypic spectrum: two young siblings 
with indications of glucocorticoid deficiency at one end 
and two patients with isolated sex steroid deficiency and 
normal stimulated cortisol levels after ACTH stimulation 
at the other. We characterised corresponding CYP17A1 
enzymatic activities in vivo, utilising urinary steroid 
profiling by gas chromatography-mass spectrometry (GC-
MS), and in vitro, employing a mammalian overexpression 
system as well as in silico modelling.
Patients and methods
Informed consent and assent, if applicable, to participate 
in this study were obtained from patients and parents, 
respectively. Patients 1–5 were recruited in the study from 
the UK Gonadal and Adrenal Inherited Disorders Network 
(Institute of Child Health/ Great Ormond Street Hospital 
Research Ethics Committee; REC number 07/Q0508/24). 
In patients 6–8, generic consent forms were employed 
that were designed following guidance published by the 
Committee on Publication Ethics (COPE) on Journal’s 
Best Practices Ensuring Consent for Medical Case Reports 
(www.publicationethics.org).
Case 1: The baby (46,XX) was born at 38 weeks 
gestation by emergency caesarean section due to foetal 
distress; birth weight was 2530 g (−1.8 SDS). Parents were 
consanguineous. She was well immediately after birth, 
not requiring neonatal intensive care support and was 
discharged on day 2 of life. She was fully bottle-fed, drinking 
90 mL term formula every 3–4 h. At 5 weeks, she was assessed 
for prolonged jaundice and poor weight gain (weight 2640 
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g, −4 SDS). There was no recorded hypoglycaemia. Her total 
bilirubin was 194 μmol/L (normal <20) with a conjugated 
fraction of 41 μmol/L. Investigations for prolonged 
conjugated jaundice, including an ultrasound of her liver, 
were normal, but random cortisol was 25 nmol/L and did 
not increase after stimulation with synacthen (Table 1). 
Plasma ACTH was highly elevated, suggesting primary 
adrenal insufficiency. 17OHP was undetectable. Serum 
potassium and sodium levels were within the normal 
range. Physical examination showed normal female 
external genitalia. Findings of urinary steroid profiling 
by GC-MS (described in results below) were consistent 
with 17α-hydroxylase deficiency, prompting initiation 
of glucocorticoid replacement. Without any further 
interventions, the girl developed well and remained on a 
dose of 10–12 mg /m2/day hydrocortisone.
Case 2: The younger sister of case 1 (46,XX) presented 
to the hospital at 8 weeks of age with failure to thrive. She 
was born small for gestational age with a birth weight of 2.6 
kg at the 42nd week of gestation (−2.7 SDS). Pregnancy and 
birth were unremarkable. Due to the loss of follow-up with 
her older sister (case 1), peri-natal investigations were not 
initiated. She had been discharged on day 2 after normal 
vaginal delivery. Her weight on admission was 3.18 kg (−3.8 
SDS). Her clinical examination was unremarkable, with 
normal female external genitalia. A random cortisol was 
undetectable, the 17OHP was low, and her electrolytes were 
within the normal range (Table 1). There was no recorded 
hypoglycaemia. Her total unconjugated bilirubin was 22 
μmol/L (normal <20). Given the family history, she was 
started on a maintenance dose of hydrocortisone (10 mg/
m2/day) and, without any further intervention, she started 
to gain weight on demand bottle feeds and remained well 
on ongoing hydrocortisone supplementation. A urinary 
steroid profile by GC-MS obtained after the initiation of 
hydrocortisone substitution showed a similar pattern 
to that of her sister, consistent with 17OHD but with 
normal concentrations of cortisol metabolites, as would be 
expected while treated.
Case 3: The patient (46,XX) was born at term with 
a weight of 2200 g (−2.7 SDS) as the third child of non-
consanguineous parents of Polish origin. Pregnancy 
and birth were uneventful. At the age of 2 years, she 
was diagnosed with hypertension and treatment with 
β-blockers and calcium antagonists was initiated. During 
childhood, the girl was frequently hospitalised due to 
electrolyte disturbances. At the age of 15 years, she was 
admitted to the paediatric endocrine service for further 
investigation of delayed pubertal development and 
hypertension. She presented with proportional body 
growth (height 168 cm (0.93 SDS), weight 49.2 kg (−0.55 
SDS)), lack of pubertal development (Tanner stages PH1, 
B2) and elevated blood pressure (150/90 mmHg, 3.56/2.98 
SDS for height), with normal sodium and low-normal 
potassium (Table 1). Further hormonal investigations 
revealed low plasma renin activity (PRA, Table 1); 
ultrasound investigations excluded renal and cardiac 
causes of hypertension. Baseline cortisol was low and did 
not increase after ACTH stimulation; 17OHP was normal 
and ACTH was elevated (Table 1). Androstenedione and 
oestradiol (E2) were low with elevated gonadotrophins, 
indicating hypergonadotropic hypogonadism (Table 1). 
Pelvic ultrasound showed a prepubertal uterus. There were 
two hypoechogenic cysts (25 and 19 mm in diameter) 
within an enlarged right ovary (20.7 cm3); the left ovary 
contained no cysts and was of normal volume (5.7 cm3).
Treatment with dexamethasone (0.5 mg/day) was 
initiated, and after 3 days, the blood pressure normalised 
to 110/70 mmHg, which was confirmed on further 
random blood pressure measurements. Two months 
later, she suffered from acute abdominal pain and an 
ultrasound examination showed enlargement of both 
ovarian cysts. Additional treatment of oestradiol (1 mg/
day) in combination with GnRH super agonist (triptorelin 
embonate, 3.75 mg/month) was initiated. Five days later, 
abdominal pain resolved, and after the second dose of 
Diphereline, both ovarian cysts regressed completely.
Case 4: The girl (46,XX) was referred to the adult 
endocrine service at the age of 17 years with primary 
amenorrhoea. She had been under regular endocrine 
surveillance since birth due to congenital hypothyroidism. 
She had been treated for essential hypertension with 
a calcium antagonist from the age of 15 years. Her 
hormonal investigations were suggestive of primary 
ovarian insufficiency. An initial MRI pelvis suggested 
absence of cervix and uterus, with a streaky left ovary 
and no right ovary visualised. Pubertal induction was 
commenced by the paediatric endocrine services at the 
age of 16 years. Further hormonal investigations revealed 
low plasma renin activity with normal electrolytes, low 
cortisol at baseline and after ACTH stimulation together 
with low 17OHP (Table 1). She was started on regular 
hydrocortisone (11.5 mg/m2/day). She remained on 
levothyroxine, spironolactone and oestradiol patches 
for pubertal induction. She has developed withdrawal 
bleeds 1.5 years after initiation of pubertal induction. 
A transabdominal ultrasound scan of her pelvis, about 
1 year after oestrogen supplementation, confirmed the 
presence of a uterus with oestrogenised endometrium 
and the presence of ovaries.
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Table 1 Summary of genetic, clinical and hormonal findings. Reference ranges (RR) for hormone measurements are shown in brackets.
Case 1* Case 2* Case 3 Case 4 Case 5§ Case 6§ Case 7 Case 8
Age at presentation 5 weeks 8 weeks 2 y 17 years birth 15 years birth 20 years
Age at investigation 5 weeks 8 weeks 15 y 17 years 12 years 15 years 23 years 20 years
Height, cm 168 164 159.6 161.1 188 158 
 SDS 0.93 0.1 0.76 −0.96 +1.6 −2.7
Weight, kg 2.62 3.16 49.2 57.7 36.1 48.5 N/A 57.85
 SDS −4 −3.6 −0.55 0.1 0.86 −0.75 N/A 1.3
BMI, kg/m2 17.4 21.5 14.2 18.7 N/A 23.1
 SDS −1.12 0.4 −2.1 −0.29 N/A 0.81
Blood pressure, 
mmHg
N/A N/A 150/90 129/89 110/80 130/69 120/75 123/71
Na, mmol/L 140 134 140 144 140 N/A 140 142
K, mmol/L 4.5 4.7 3.5 4.2 4.0 N/A 4.2 4.6
Renin/PRA 0.37 ng/mL/h <5.0 ng/L 1.5 ng/mL/h 1.0 nmol/L/h
 RR 0.5–2.6 3.6–20.1 0.5–2.6 0.3–2.2
Aldosterone, pmol/L <30 0.31 204 
 RR 50–470 0.1–0.8 <630
Cortisol, nmol/L
 At baseline <25 <25 136 (>150) <20 105 (>150) 113 (>150) 375 (>150) 467
 60’ ACTH1–24 33 (>550) 198 (>550) 30 (>500) 151 (>550) 150 (>550) 621 (>550) 512 (>450)
17OHP, nmol/L <1 (2–10) 1.5 (2–10) 2.85 (<5) <0.3 (2–9) 17.4 (<5) 2.7 (<5) 22.1 (0.9–6.6) 28.4 (2–9)
ACTH, pmol/L 85 (<10) 110 (2–10) 15.4 (2–10) 7.7 (2–10) 9.5 (2–10) 4.2 (2–10) 10.2 (2–10)
DHEAS, µmol/L <0.4 (1.7–10.1) <0.05 0.4 (1–4) < 0.4 (1.7–10.1) 0.98 (5.2–
12.3)
3.3 (5.2–12.3)
Testosterone, nmol/L <0.1 2.4 (0.4–9.5) 0.96 (11–35) 6.9 (9.2–55.8)
Oestradiol, pmol/L <70 <100 43 116 (30–180) 91 (95–228)
LH, U/L 18.4 (0.4–5.7) 33.1 24.4 (0.4–5.7) 2.4 (0.4–5.7) 14 (1–9) 20.0 (1.7–8.6)
FSH, U/L 15.3 (2.7–4.4) 105.1 14.2 (2.7–4.4) 4.3 (2.7–4.4) 21 (1–12) 5.4 (1.5–12.4)















 P N/A N/A Pro409Leu N/A Phe53/54del Phe53/54del N/A N/A
 M Tyr60Ilefs*29 Tyr60Ilefs*29 Gly111Val N/A Phe53/54del Phe53/54del N/A N/A
Novel mutations are highlighted in bold.
*/§Siblings.
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Case 5: The boy (46,XY) is the fourth child of 
consanguineous parents of Afghan origin, with no 
available information on pregnancy and birth. He 
presented at the age of 12 years with learning difficulties, 
gynecomastia, micropenis (stretched length 2.5 cm; <3rd 
centile), glandular hypospadias and cryptorchidism and 
had a history of orchidopexy for a left undescended testis 
in the age of 5 years. Tanner stages: G1, PH3, testicular 
volumes were 1 mL on the right and 4 mL on the left. 
His blood pressure was normal, serum potassium and 
sodium levels were within a normal range (Table 1). His 
serum testosterone was within the lower normal age- and 
sex-specific range while gonadotrophins were increased, 
in keeping with compensated hypergonadotropic 
hypogonadism (Table 1). Baseline cortisol was low and did 
not increase after i.v. synacthen; 17OHP at baseline was 
elevated (Table 1).
Case 6: The older sister (46,XX) of case 5 presented to 
the endocrine clinic at the age of 15 years because of the 
family history and delayed pubertal development. Her 
previous medical history including pregnancy and birth 
was unremarkable. She had normal breast development 
(Tanner B4) but there was an absence of menarche and 
pubic hair growth. Serum cortisol was low at baseline and 
did not increase sufficiently after i.v. synacthen (Table 1). 
Serum 17OHP was 2.7 nmol/L at baseline and increased to 
3.5 nmol/L after synacthen stimulation. Baseline DHEAS 
was undetectable. Serum oestradiol was prepubertal with 
gonadotrophins at baseline within the pubertal reference 
range (Table 1). Blood pressure was normal at several 
random measurements and within the age- and height-
adjusted 50th–90th centiles in a 24 h blood pressure 
measurement.
Case 7: The patient (46,XY) was born as the only child 
of non-consanguineous parents of Caucasian origin in 
Romania. He presented to the joint endocrine and urology 
services at the age of 23 years with a wish for phalloplasty 
and to evaluate his fertility. There are no details available 
regarding pregnancy, birth and medical history. According 
to the patient, he was born with a bifid scrotum and an 
‘absent phallus’. He was raised as a boy and received multiple 
testosterone injections during childhood and adolescence. 
He underwent two unspecified genital surgeries, one at 
3 months and another at 3 years of age. At the age of 16 
years, bilateral gynecomastia was surgically removed. On 
examination, there was a single perineal opening with 
no phallus. Both testicles were small; the left testicle was 
palpable in the inguinal region; the right was found in a 
bifid scrotum. Blood pressure was normal when measured 
randomly and over 24 h. Hormonal investigations showed 
normal cortisol levels at baseline and after synacthen 
stimulation (Table 1). His 17OHP was elevated (Table 1), 
a corresponding 17Preg level was normal (7.9 nmol/L; NR 
<13.3); the ACTH was within the reference range (Table 1). 
Sodium, potassium, renin and aldosterone were normal 
(Table 1). DHEAS and testosterone were both low, with 
elevated baseline gonadotrophins (Table 1).
Case 8: The patient (46,XY) presented to the adult 
endocrine service with right-sided gynecomastia at the 
age of 20 years. He was born in Pakistan to consanguineous 
parents (first cousins). He reported having two operations 
to correct hypospadias, completed at the age of 7 years 
before the family moved to the UK. He has had bilateral 
mammoplasty during adolescence, but the gynaecomastia 
was refractory to surgical treatment on the right due to 
residual breast tissue. On examination, there was no 
genital ambiguity and his external genitalia appeared male 
with testicular volumes of 9 (left) and 13 mL (right). He 
had appropriate amounts of pubic and axillary hair. His 
stretched penile length was 9 cm (below 10th centile). 
His blood pressure was normal with normal electrolytes 
and plasma renin activity (Table 1). His 17OHP was mildly 
elevated and an early morning ACTH was at the upper 
limit of normal; he had adequate cortisol response after 
synacthen stimulation (Table 1). Serum testosterone level 
was slightly below the normal adult male range with 
elevated LH and normal FSH, indicating hypergonadotropic 
hypogonadism (Table 1). Imaging studies of his adrenals 
and testicles did not reveal any pathology; the adrenals 
were of normal size. He was commenced on testosterone 
undecanoate 1 g every 12–14 weeks, following sperm 
cryopreservation. Following testosterone replacement, 
he experienced an increase in muscle bulk, beard growth, 
penile growth and disappearance of palpable breast tissue.
Urinary steroid profiling by gas chromatography-
mass spectrometry (GC-MS)
Analysis of urinary steroid metabolite excretion was 
performed as described previously by a quantitative 
GC-MS selected ion-monitoring (SIM) method (15). 
In brief, steroids were enzymatically released from 
conjugation and, after extraction, chemically derivatised 
before GC-MS SIM analysis. Steroids quantified included 
corticosterone metabolites (tetrahydrocorticosterone 
(THB), 5α-tetrahydrocorticosterone (5αTHB) and 
tetrahydro-11-dehydrocorticosterone (THA)), the 
17-hydroxyprogesterone metabolites 17-hydroxy-
pregnanolone (17HP) and pregnanetriol (PT), the 
pregnenolone metabolite pregnenediol (5PD), the 
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17-pregnenolone metabolite 5-pregnenetriol (5PT), 
cortisol metabolites (tetrahydrocortisol (THF), 
5α-tetrahydrocortisol (5αTHF), tetrahydrocortisone 
(THE), cortolones and cortols and androgen metabolites 
(androsterone (An) and etiocholanolone (Et), DHEA 
(DHEA)). Additional steroids that are important 
in the newborn period were quantified in Case 1: 
16α-hydroxy-dehydroepiandosterone (16α-OH-DHA), 
16α-hydroxypregnenolone 5αTHA, 5αTHF and 6α-hydroxy 
tetrahydro-11-dehydrocorticosterone (6a-OH-THA).
Following the quantification of steroid metabolites, 
we calculated substrate metabolite to product 
metabolite ratios to determine the approximate in vivo 
net activities of CYP17A1: corticosterone over cortisol 
metabolites (17α-hydroxylase; (THA+THB+5αTHB)/
(THF+5αTHF+THE)), and 17-hydroxyprogesterone over 
androgen metabolites (17,20-lyase; (17HP+PT)/(An+Et) 
and 5PT/DHEA). The diagnostic ratios were compared to 
data obtained from a healthy reference cohort (males and 
females, aged 10–30 years, n  = 28).
Sequencing and analysis of sequence variants
We carried out sequencing analysis for cases 1, 2, 3, 4, 5 and 
6 as described previously (16). CYP17A1 gene analysis in 
genomic DNA from cases 7 and 8 was performed by genetic 
service laboratories accredited by the National Health 
Service, England. Sequencing analysis was performed 
using Lasergene® software (DNASTAR Inc., Madison, USA), 
and mutation numbering was carried out referring to 
the CYP17A1 NCBI reference sequences Chr10(GRCh38) 
(genomic), NM_000201.4 (cDNA) and NP_000093 
(protein). Allele frequencies and REVEL (Rare Exome 
Variant Ensemble Learner) scores, an ensemble method 
for the prediction of missense variants (17), were obtained 
with the gnomAD 3.1.1 software.
In silico analysis
The crystal structure of human CYP17A1 (http://www. 
rcsb.org/pdb, PDB code 3RUK) was used to analyse the 
impact of non-synonymous sequence variants on the 
three-dimensional structure of the CYP17A1 enzyme using 
the Molsoft ICM Browser Pro Software (Molsoft L.L.C, La 
Jolla, CA, USA).
In vitro functional studies
The mammalian expression vector pcDNA6-V5-6xHis(B) 
(Invitrogen) was used for in vitro functional assays in 
HEK293 cells. Plasmids containing either the WT human 
CYP17A1 or mutant sequences were synthesised by 
GenScript Biotech (Amsterdam, The Netherlands). The stop 
codon in the ORF was removed to add a C-terminal V5-tag. 
All constructs were confirmed by Sanger sequencing.
Transfection was carried out as described previously 
(6). A ratio of 2 µg of plasmid DNA to 6 µL of FuGENE®HD 
transfection reagent per six-well was employed. Forty-
eight hours after transfection, cells were incubated at 37°C 
with 1 mL full MEM supplemented with 1000 nmol/L 
progesterone for 17α-hydroxylase assays or 500 nmol/L 
17Preg for 17,20-lyase assays. Substrate concentrations 
were chosen as they are near the Km of the WT enzyme. 
Optimal incubation times for obtaining linear conversion 
rates were assessed for WT and mutants in preceding pilot 
experiments and were 30 min for 17α-hydroxylase and 60 
min for 17,20-lyase.
After incubation, 20 ng of each deuterated 
progesterone, 17OHP, 17Preg, DHEA, and androstenedione 
(all Cambridge Isotope Laboratories Inc., Andover, MA) 
was added to the medium as an internal standard to 
normalise for extraction efficiency. Steroids were extracted 
from 500 µL of spiked medium with 1.5 mL methyl tert-
butyl ether (MTBE, Sigma–Aldrich) as described previously 
(18). A Waters Xevo mass spectrometer with ACQUITY 
ultra performance liquid chromatography™ (UPLC) system 
was used fitted with an HSS T3, 1.8 µM, 1.2 × 50 mm 
column (Waters Corporation, Milford, MA). Each steroid 
was quantified by comparison to a calibration series 
with respect to their internal standard. Quantitation was 
completed using TargetLynx 4.1 software (MassLynx 4.1, 
Waters). Conversion rates of CYP17A1 activities were 
determined as micrograms per milligram of total protein 
per minute and expressed as a percentage of substrate 
conversion defining WT activity as 100%. Data analysis was 
facilitated and graphically illustrated using the GraphPad 
Prism software version 5.0 (GraphPad Inc. ).
Results
Sequencing analysis
The identified CYP17A1 sequence variants are summarised 
in Table 1 (protein level) and Supplementary Table 1 (see 
section on supplementary materials given at the end of 
this article) (full HGVS nomenclature). Parental DNA 
for segregational analysis was available for cases 1–3, 5 
and 6. Of the eight sequence variants identified, three 
have not been reported before (p.Gly111Val, p.Ala398G, 
p.Ile371Thr). Three sequence variants (p.Pro409Leu, 
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Gly436Arg and p.Tyr60IlefsLys88X) have been described 
in clinical case reports but without activity assays (19, 20), 
while reports of two (p.Phe53/54del, p.Arg347His) have 
included activity assays (10, 14). All sequence variants 
have low allele frequencies, and pathogenicity prediction 
of the missense variants revealed REVEL scores of >0.5, 
suggesting that they are likely pathogenic (see 
Supplementary Table 1).
Urinary steroid profiling
All patients had received a diagnosis by urinary steroid 
profiling in various laboratories. Stored samples were 
reanalysed for this study, with the exception of neonatal 
cases 1 and 2 and case 4, who had already been started 
on hydrocortisone replacement (Fig. 1). All showed a 
typical pattern, with elevated metabolites of steroids in 
the mineralocorticoid pathway, elevated progesterone and 
pregnenolone metabolites (5-PT, PT, and 5-PD), but low 
androgen metabolites (An and Et) and borderline to very low 
metabolites of cortisol (THF, 5α-THF, cortolones and cortols). 
We employed substrate: product ratios reflecting the in vivo 
catalytic activities for CYP17A1 17α-hydroxylase and 17,20-
lyase activities. The ratio reflecting 17α-hydroxylase activity 
((THA+THB+5aTHB)/(THE+THF+5aTHF)) was most severely 
impaired in case 3, presenting with a classical phenotype 
(185.7; NR 0.07–0.18), moderately elevated in cases 5 and 
6, presenting with a moderate phenotype (6.8 and 12.3, 
respectively) and mildly elevated in cases 7 and 8, presenting 
with a mild phenotype (1.7 and 1.62, respectively) (Fig. 1). 
We have employed two ratios reflecting CYP17A1 17,20-
lyase activities: ((17HP+PT)/(An+Et)) in the Δ4 and 5PT/
DHEA in the Δ5 pathway. Both ratios were elevated above 
the reference range for all cases ((17HP+PT)/(An+Et): 1.15–
10.1 (NR 0.09–0.31); 5PT/DHEA: 7.6–138.3 (NR 0.2–3.7); Fig. 
1). GC-MS chromatograms for case 1 (Supplementary Fig 1) 
showed changes consistent with our previous findings for 
severely affected newborns (21). These comprise increase of 
THA + 5αTHA/THE + 5αTHE: 37.2 (normal: 0.25) and a very 
high ratio of 16α-hydroxypregnenolone /16α-OH-DHEA: 
>200 (normal about unity).
In silico analysis of non-synonymous 
sequence variants
Gly111Val (case 3, classic phenotype)
Glycine 111 is in close proximity to extended helix between 
threonine 294 and threonine 295, down to a distance 
of 3.9 Å between Gly111 and Thr294. This Thr294 side 
chain is shown in ball representation and grey in Fig. 2B. 
Introducing the bulkier valine instead of Gly111 would 
result in a steric clash, impairing protein function.
Pro409Leu and Gly436Arg (cases 3 and 4, 
classic phenotypes)
Proline 409 and Glycine 436 are both located in an 
extended loop structure ranging from asparagine 402 to 
Glycine 444 (this loop is highlighted in green in Fig. 2C and 
F). Glycine 436 is a highly conserved residue, embedded 
in an extended loop structure in close contact with the 
haeme co-factor. Gly436 is needed for a hairpin loop 
beginning at Pro434. Exchanging glycine 436 even with 
the much bigger arginine will certainly disturb folding 
and interfere with co-factor binding due to steric clashes. 
The loop region around Pro409 is rather stable according 
to structural thermal factors. Most likely, it is the unique 
properties of the amino acid proline that are required to 
initiate a tight loop including Asp410 and to stiffen the 
peptide backbone. Even exchanging proline with the 
similarly sized hydrophobic amino acid leucine will most 
likely destabilise the protein fold.
Ala398Glu (case 7, mild phenotype)
Alanine 398 sits in a relatively polar pocket (Fig. 2D). One 
of the polar amino acids is glutamine 57, which forms a 
hydrogen bond with the glycine 77 main chain oxygen. 
Figure 1
In vivo assessment of CYP17A1 17α-hydroxylase and 17,20-
lyase activities as indicated by urinary steroid metabolite 
analysis. Individual diagnostic steroid metabolite ratios in the 
five 17OHD cases analysed are represented by the symbols as 
indicated in the legend. Phenotypes with a mild phenotype 
(cases 7 and 8) are represented as white, intermediate 
phenotypes (cases 5 and 6) as grey and one case with a severe 
phenotype (case 3) as black symbols. White box plots 
represent the interquartile ranges of the reference cohort 
(healthy males and females, 10–30 years; n  = 28), whiskers 
represent the 5th and 95th percentiles, respectively. For 
steroid abbreviations please see methods.
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Introducing glutamate instead of alanine 398 may 
break this hydrogen bond but could offer opportunities 
for compensating interactions with glutamine 57 or 
asparagine 395 as the potential binding partners. Hence, 
this exchange is expected only to mildly influence 
protein function.
Ile371Thr (case 8, mild phenotype)
Isoleucine 371 is in close proximity to arginine 96 (3.4Å) 
and in spatial proximity to the haem co-factor (Fig. 2E). 
Threonine is smaller than isoleucine but fits well into the 
overall shape of isoleucine. An isoleucine to threonine 
exchange at this buried site is expected not to cause 
any steric clash and would impair protein function 
only mildly.
We have used the structural model for a CYP17A1-b5-
POR complex (22) to test whether any of the mutations 
from this study could interfere with redox partner 
binding. According to this model, none of the mutations 
described here is likely to interfere with b5 and/or 
POR binding.
Figure 2
Three-dimensional model of CYP17A1 (RCSB protein databank identifier: 3RUK). Panel A provides an overview of the CYP17A1 
model and sequence variants (as WT residues) identified in this case series. Panel B, C, D, E and F magnify the mutated amino acid 
residues to illustrate the impact of the mutations within their immediate environment.
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In vitro functional analysis
All mutants assessed for the residual enzymatic activity 
of both catalytic reactions of CYP17A1 showed greatly 
reduced or absent activity in our cell-based in vitro 
system (Fig. 3). Four mutants (p.Ile371Thr, p.Arg347His, 
p.Ala398Glu and p.Phe53/54del) retain some residual 
activity on 17α-hydroxylase function with about 10–15% 
of WT activity (Fig. 3A). Amongst these, the p.Ile371His 
and the p.Arg347Arg mutations, found in the cases 7 
and 8 with a mild phenotype, have the highest residual 
activity (14.0 ± 1.2% and 13.3% ± 2.6%, respectively) 
with p.Ala398Glu and p.Phe53/54del retaining 
5.8 ± 1.3% and 5.9 ± 1.4%, respectively, of WT enzyme 
activity. In p.Gly111Val, p.Pro409Leu, p.Gly436Arg and 
Tyr60IlefsLys88X, found in cases with severe phenotypes, 
17α-hydroxylase activity was abolished in our assay 
system (Fig. 3A). 17,20-lyase activity was greatly reduced 
or abolished for all mutant CYP17A1 proteins studied 
(Fig. 3B). The p.Ile371Thr mutation, found in case 8 with 
a mild phenotype, retained the highest degree of residual 
activity (3.6±0.9%). The p.Ala398Glu, p.Phe53/54del and 
p.Pro409Leu retained residual enzyme activity at 1.5% of 
wild-type. The residual 17,20-lyase activity is abolished for 
the p.Arg347His, the p. Gly111Val, the Gly436Arg and the 
frameshift mutations (Fig. 3B).
Discussion
Our case series refines the phenotypic spectrum of 17OHD, 
describing eight patients with inactivating mutations 
in the CYP17A1 gene and assessing their functional 
impact in vivo by urinary steroid profiling analysis and 
in vitro by functional studies. This showed that residual 
CYP17A1 17α-hydroxylase activity is associated with the 
severity of this condition. Four of our cases present with 
extreme phenotypes: failure to thrive and conjugated 
hyperbilirubinemia in our siblings (cases 1 and 2) prompted 
investigations into adrenal insufficiency caused by a severe 
homozygous frameshift mutation, and, at the other end of 
the scale, cases 7 and 8 exhibited a normal cortisol increase 
in response to ACTH.
The majority of patients with combined 
17α-hydroxylase/17,20-lyase deficiency due to severely 
inactivating CYP17A1 mutations first present with a lack of 
pubertal development and low renin hypertension. They 
may be found to be 46,XX, as in cases 3 and 4, or 46,XY. 
Patients with milder mutations who are 46,XX may present 
with less overt pubertal delay and be normotensive, as in 
case 6, while 46,XY individuals may present at birth with 
genital ambiguity, although diagnosis may be significantly 
delayed, as in cases 5, 7 and 8.
Figure 3
Residual mutant enzyme activity values are shown for the two 
catalytic activities of CYP17A1. Panel A for the conversion of 
progesterone (Prog) to 17-hydroxyprogesterone (17OHP), 
reflecting 17α-hydroxylase activity; panel B reflects the 
17,20-lyase activity as assessed by the conversion of 
17-hydroxypregnenolone (17Preg) to DHEA. Residual enzyme 
activity is expressed at the percentage of WT activity, which is 
defined as 100%. Substrate conversion rate for WT protein 
was 14.4 ± 0.4 nmol/mg protein/min for Prog and 5.8 ± 1.5 
nmol/mg protein/min for 17Preg. All experiments were 
performed in triplicate in three independent experiments, and 
each data point represents the median of each triplicate.
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Cortisol deficiency in 17OHD is appropriately 
compensated by activation of the HPA axis to maintain 
the required level of alternative glucocorticoid, primarily 
corticosterone, an intermediate in the mineralocorticoid 
pathway (1, 23, 24). Cases 1 and 2 had increased 
corticosterone metabolite excretion in the neonatal 
urinary steroid profile, but failure to thrive, and also 
conjugated hyperbilirubinaemia in case 1, which 
may reflect clinical signs of early onset glucocorticoid 
deficiency. A recent case report of a 46,XX girl harbouring 
the same frameshift mutation in homozygosity as 
cases 1 and 2 presented in adolescence with primary 
amenorrhoea, but details of her neonatal course were 
not provided (20). Similarly, three Turkish siblings with 
large-range deletions in CYP17A1 abolishing enzymatic 
activity presented with severe hypertension and primary 
amenorrhoea, but early onset adrenal insufficiency has 
not been reported by the authors (25). While contributing 
factors such as stress, infections or sepsis are reported 
to trigger adrenal crisis in 17OHD, as exemplified in the 
very first reported case by Biglieri (26), these had been 
excluded at the time of presentation in our siblings. Both 
siblings recovered after initiation of physiological doses of 
hydrocortisone alone, and other causes of failure to thrive 
and conjugated jaundice were excluded. Importantly, the 
findings from the urinary steroid profiling analysis were 
instrumental in excluding other causes of primary adrenal 
insufficiency (i.e. mutations in NR5A1, StAR, CYP11A1 or 
HSD3B2). Multi-steroid profiling by LC-MS/MS has also 
been shown to be highly effective in detecting CYP17A1 
deficiency early (27) but was not available. Given the 
consanguineous background of our siblings, concomitant 
mutations in other genes causing adrenal insufficiency 
might have contributed to the phenotype, a rare possibility 
that we were not able to address. However, it does appear 
that phenotypic severity varies even in severely predicted 
CYP17A1 genotypes, as exemplified by a report of an 
adult prepubertal woman with an early truncation of the 
CYP17A1 protein (homozygous p.Y27X) who did not even 
develop hypertension (28). Different phenotypes with the 
same genotype or even family background are recognised 
in CAH, and genetic variation in other genes or co-factors 
of steroidogenesis may contribute to this phenotypic 
variability (29). 'However, on balance, we are not able to 
conclusively prove that glucocorticoid deficiency due 
to 17OHD has caused the symptoms observed in these 
siblings since electrolyte abnormalities and significant 
hypotension/shock were absent. The clinical signs were 
subtle and relatively non-specific, nevertheless prompted 
the clinician to investigate for adrenal pathology'.
Activation of the HPA axis also drives increased 
production of the corticosterone precursor, 
11-deoxycorticosterone (DOC), a weak mineralocorticoid; 
18-hydroxylated products of both steroids also have 
mineralocorticoid activity. This tends to suppress the 
renin-angiotensin-aldosterone system via blood pressure 
increase and hypokalaemia. In severe 17OHD, this is 
insufficient to compensate for the mineralocorticoid 
excess, resulting in hypertension and hypokalaemia, as 
in the classic presentations of patients 3 and 4. Milder 
deficiencies can be compensated, as seen in patients 5–8. 
Notwithstanding the above, about 10% of patients with 
severe 17OHD are normokalaemic and normotensive (30). 
This also suggests that there is considerable phenotypic 
variability, with perhaps both additional compensatory 
mechanisms and forms of compensatory failure.
Cases 7 and 8 presented with the clinical and 
biochemical features of so-called ‘isolated 17,20-lyase 
deficiency’. This is a rare condition and only around 30 
cases have been described in the literature (6, 12, 13, 14, 31, 
32). Initial reports provided only clinical and hormonal 
characterisation without identifying a distinct genetic 
abnormality in six families with 46,XY DSD and two 
families with 46,XX patients that presented with lack of 
pubertal development (reviewed and discussed in (1, 6)). 
So far, 17 cases of ‘isolated’ 17,20-lyase deficiency with 
a complete clinical, hormonal, genetic and functional 
work-up have been reported. Underlying causes were 
four distinct missense mutations in the CYP17A1 gene 
(p.Arg347His; p.Arg347Cys p.Arg358Gln; p.Glu305Gly) 
(12, 13, 14) and one POR missense mutation (p.Gly539Arg) 
(31). A total of six patients with CYB5A mutations have 
been reported so far (32, 33) and these exhibit the purest 
form of isolated 17,20-lyase deficiency. CYB5A exclusively 
supports CYP17A1 17,20-lyase activity, as shown by 
comprehensive clinical and biochemical phenotyping as 
well as in vitro functional analysis in an affected kindred 
with the p.His44Lys mutation (6).
Case 7 carried the known missense mutation 
p.Arg347His on one allele (14) and a novel missense 
mutation p.Ala398Glu on the other allele. According to 
our in vitro functional analysis, the p.Ala398Glu has only 
5.8% residual activity compared to p.Arg347His, which 
retains 13.3% of WT activity. The finding that our patient 
has normal stimulated cortisol levels is due to the effect of 
the milder p.Arg347His mutation. Case 8 carries the novel 
p.Ile371Thr mutation in homozygosity and also presented 
with some degree of sex steroid deficiency/primary 
hypogonadism and normal cortisol levels after ACTH 
stimulation. It is remarkable that his serum testosterone 
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concentration was within the lower male reference range 
despite a severe degree of genital ambiguity at birth. This 
may indicate that testicular testosterone production during 
embryonic development is more severely affected compared 
to puberty, which is surprising since accumulating 17OHP 
due to deficient 17,20-lyase in the foetal testis should feed 
into the alternative pathway towards dihydrotestosterone 
generation (4, 34). Further studies on p.Ile371Thr could 
explore the possibility that this CYP17A1 variant has 
reduced affinity for 5-pdiol, the substrate of 17,20-lyase in 
the alternative pathway. Genital ambiguity in 46,XY has a 
relatively high population prevalence and a molecular basis 
is not established in most cases (35), so a multi-factorial 
cause in our patient is possible. The data from our in vitro 
functional analysis concur with the clinical findings: the 
17α-hydroxylase activity was 14%, a similar level to the 
p.Arg347His mutation, but it also retained some residual 
17,20-lyase activity.
At the time of assessment, 46,XY patients 7 and 8 
had high serum levels of 17OHP, as did case 5, who had 
a much higher level than his 46,XX sibling, case 6. This 
likely reflects predominantly enhanced testicular 17OHP 
production under LH hyperstimulation. This is supported 
by the urine steroid data, which showed increases above 
normal of the 17OHP metabolites 17HP and PT but 
not of 11-oxopregnanetriol, the major metabolite of 
21-deoxycortisol and a marker of adrenal 17OHP excess. 
This indicates a predominantly testicular origin for the 
17OHP. Prepubertal XY patients with 17OHD have been 
reported to show increased 17OHP after hCG stimulation 
but not after synacthen.
To our knowledge, cases 7 and 8 have the mildest ever 
reported phenotype for disease-causing mutations in 
CYP17A1 and are probably closest to what was previously 
described as ‘isolated’ 17,20-lyase deficiency in the context 
of 17OHD. A unifying characteristic of all individuals with 
‘isolated’ 17,20-lyase deficiency is sex steroid deficiency, 
with hormonal measurements confirming diminished 
adrenal and gonadal androgen synthesis. All previously 
reported patients with an apparent isolated 17,20-lyase 
deficiency with underlying CYP17A1 or POR mutations 
have shown impairment of cortisol production, with 
insufficient responses to ACTH stimulation (6). In contrast, 
cases 7 and 8 are the first reported 17OHD patients who have 
normal ACTH-stimulated cortisol levels. Nevertheless, 
urinary steroid analysis demonstrated impairment of 
17α-hydroxylase activity. Compared to the ratios we have 
obtained from patients with classical 17OHD or partial 
combined 17α-hydroxylase/17,20-lyase deficiency (cases 
5 and 6), their corticosterone/cortisol metabolite ratios 
are lower, suggesting higher residual in vivo CYP17A1 
17α-hydroxylase activity in milder cases. Thus, a precursor/
product ratio of corticosterone over cortisol metabolites 
reflecting in vivo 17α-hydroxylase activity correlates well 
with the severity of the disease and may help to predict 
the phenotype (Fig. 1). This finding is in accord with two 
previous studies employing GC-MS steroid metabolome 
analysis in 17OHD subjects with severe (36) and milder (37) 
disease manifestation. Interestingly, the diagnostic ratios 
reflecting CYP17A1 17,20-lyase activity in our patients are 
higher in milder cases (cases 7 and 8) suggesting severe 
impairment (Fig. 1). Severe 17α-hydroxylase attenuation 
in more severe disease results in the reduction of 
17-hydroxylated metabolites that build the numerator for 
both ratios. Hence, neither 17,20-lyase ratios reflect the 
in vivo residual activity in CYP17A1 due to concomitant 
17α-hydroxylase inhibition.
In our functional analysis, we have not performed 
enzyme kinetic studies in WT and mutant protein to 
determine Vmax and Km, thus the reported residual 
activity at a fixed concentration, around the Km of the 
substrates of the WT protein, is a combination of both 
effects. This is a limitation of our work, however, enables 
the determination of the disease-causing effects of the 
variants and characterises their differential impact on 
17α-hydroxylase and 17,20-lyase activities.
In summary, our case series illustrates the broad 
phenotypic variability of CYP17A1 deficiency and, 
importantly, expands both ends of this spectrum. 
These range from early presentation to isolated sex 
steroid deficiency with normal stimulated cortisol 
production, respectively. Urinary steroid profiling by mass 
spectrometry represents a powerful diagnostic tool not 
only in establishing the diagnosis but also in predicting 
the severity of the phenotype (38).
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